| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology (Drs. Kracke, Dalley, Windhagen, Heidenreich) and Rheumatology (Dr. Al-Masri), Hannover Medical School, Hannover, Germany; and the Sophien Klinik Hannover (Dr. von Wussow), Hannover, Germany.
Address correspondence and reprint requests to Dr. F. Heidenreich, Department of Neurology-OE 7210, Hannover Medical School, D-30623 Hannover, Germany; e-mail: heidenreich.fedor{at}mh-hannover.de
OBJECTIVE: To correlate Mx protein (Mx) levels in lysed blood leukocytes with the clinical response to interferon (IFN) beta-1b (IFNß-1b) in relapsing–remitting MS (RR-MS) patients for monitoring treatment.
BACKGROUND: Intracellular Mx expression is exclusively induced by the type I IFNs (IFN-
, -ß, and -
) or by viruses and is strongly increased under IFN treatment. Quantitative determination of Mx allows objective assessment of biological effects of IFN.
METHODS: Mx protein levels were measured in blood leukocyte lysates from IFNß-1b-treated RR-MS patients by ELISA and correlated to clinical parameters, including relapse rate and clinical deterioration.
RESULTS: In stable IFNß-1b-treated MS patients, Mx levels were significantly increased compared to patients with or without immunosuppressive treatment. In IFNß-1b-treated MS patients during relapse, Mx levels were significantly lower than during stable phases of the disease. Mean values of Mx (MVMx) over time of treatment in patients with a reduction of relapse rate were significantly higher than in patients without response.
CONCLUSION: Mx levels in lysed blood cells may represent a useful surrogate marker for IFNß-1b activity corresponding to the clinical response during treatment of MS.
Key words: MS—Mx proteins—Interferon beta
This article has been cited by other articles:
|
|
 |
|
  A. W. Chiu, N. Richert, M. Ehrmantraut, J. Ohayon, S. Gupta, G. Bomboi, D. Gaindh, F. K. Cantor, J. A. Frank, H. F. McFarland, et al. Heterogeneity in Response to Interferon Beta in Patients With Multiple Sclerosis: A 3-Year Monthly Imaging Study Arch Neurol, January 1, 2009; 66(1): 39 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Rio, A Rovira, M Tintore, E Huerga, C Nos, N Tellez, C Tur, M Comabella, and X Montalban Relationship between MRI lesion activity and response to IFN-{beta} in relapsing-remitting multiple sclerosis patients Multiple Sclerosis, May 1, 2008; 14(4): 479 - 484. [Abstract] [PDF]
|
|
|
|
|
|
K. Hamamcioglu and A. Reder Interferon-{beta} regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis Multiple Sclerosis, May 1, 2007; 13(4): 459 - 470. [Abstract] [PDF]
|
|
|
|
|
|
E Portaccio, V Zipoli, G Siracusa, S Sorbi, and M P Amato Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria Multiple Sclerosis, June 1, 2006; 12(3): 281 - 286. [Abstract] [PDF]
|
|
|
|
|
|
F Gilli, F Marnetto, M Caldano, A Sala, S Malucchi, M Capobianco, and A Bertolotto Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1 Multiple Sclerosis, February 1, 2006; 12(1): 47 - 57. [Abstract] [PDF]
|
|
|
|
 |
|
 A Bertolotto, A Sala, S Malucchi, F Marnetto, M Caldano, A Di Sapio, M Capobianco, and F Gilli Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies J. Neurol. Neurosurg. Psychiatry, September 1, 2004; 75(9): 1294 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Malucchi, A. Sala, F. Gilli, R. Bottero, A. Di Sapio, M. Capobianco, and A. Bertolotto Neutralizing antibodies reduce the efficacy of {beta}IFN during treatment of multiple sclerosis Neurology, June 8, 2004; 62(11): 2031 - 2037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Pachner, A. Bertolotto, and F. Deisenhammer Measurement of MxA mRNA or protein as a biomarker of IFN{beta} bioactivity: Detection of antibody-mediated decreased bioactivity (ADB) Neurology, November 11, 2003; 61(90095): S24 - 26. [Abstract] [Full Text]
|
|
|
|
|
|
E. Waubant, S. Vukusic, L. Gignoux, F. D. Dubief, I. Achiti, S. Blanc, C. Renoux, and C. Confavreux Clinical characteristics of responders to interferon therapy for relapsing MS Neurology, July 22, 2003; 61(2): 184 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bertolotto, F. Gilli, A. Sala, M. Capobianco, S. Malucchi, E. Milano, F. Melis, F. Marnetto, R. L.P. Lindberg, R. Bottero, et al. Persistent neutralizing antibodies abolish the interferon {beta} bioavailability in MS patients Neurology, February 25, 2003; 60(4): 634 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Kob, J Harvey, F Schautzer, S Kascha, D Bibl, R Egg, M Reindl, T Berger, and F Deisenhammer A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta Multiple Sclerosis, February 1, 2003; 9(1): 32 - 35. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Gromov, G. L. Skovgaard, H. Palsdottir, I. Gromova, M. Ostergaard, and J. E. Celis Protein Profiling of the Human Epidermis from the Elderly Reveals Up-regulation of a Signature of Interferon-{gamma}-induced Polypeptides That Includes Manganese-superoxide Dismutase and the p85{beta} Subunit of Phosphatidylinositol 3-Kinase Mol. Cell. Proteomics, February 1, 2003; 2(2): 70 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Burks, B. G. Arnason, P. K. Coyle, C. C. Ford, A. Noronha, and K. W. Rammohan Issues and Practices in Multiple Sclerosis Neurorehabil Neural Repair, December 1, 2002; 16(4): 307 - 320. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Muller-Doblies, M. Ackermann, and A. Metzler In Vitro and In Vivo Detection of Mx Gene Products in Bovine Cells following Stimulation with Alpha/Beta Interferon and Viruses Clin. Vaccine Immunol., November 1, 2002; 9(6): 1192 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Abel, M. J. Alegria-Hartman, K. Rothaeusler, M. Marthas, and C. J. Miller The Relationship between Simian Immunodeficiency Virus RNA Levels and the mRNA Levels of Alpha/Beta Interferons (IFN-{alpha}/{beta}) and IFN-{alpha}/{beta}-Inducible Mx in Lymphoid Tissues of Rhesus Macaques during Acute and Chronic Infection J. Virol., July 17, 2002; 76(16): 8433 - 8445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. Vallittu, M. Halminen, J. Peltoniemi, J. Ilonen, I. Julkunen, A. Salmi, J.-P. Eralinna, and the Finnish Beta-Interferon Study Group Neutralizing antibodies reduce MxA protein induction in interferon- beta-1a-treated MS patients Neurology, June 25, 2002; 58(12): 1786 - 1790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Charleston, M. D. Fray, S. Baigent, B. V. Carr, and W. I. Morrison Establishment of persistent infection with non-cytopathic bovine viral diarrhoea virus in cattle is associated with a failure to induce type I interferon J. Gen. Virol., August 1, 2001; 82(8): 1893 - 1897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Reder and J. P. Antel Injecting rationale into interferon-{beta} therapy Neurology, June 13, 2000; 54(11): 2034 - 2035. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
